Type I interferon signaling attenuates regulatory T cell function in viral infection and in the tumor microenvironment

PLoS Pathog. 2018 Apr 19;14(4):e1006985. doi: 10.1371/journal.ppat.1006985. eCollection 2018 Apr.

Abstract

Regulatory T cells (Tregs) play a cardinal role in the immune system by suppressing detrimental autoimmune responses, but their role in acute, chronic infectious diseases and tumor microenvironment remains unclear. We recently demonstrated that IFN-α/β receptor (IFNAR) signaling promotes Treg function in autoimmunity. Here we dissected the functional role of IFNAR-signaling in Tregs using Treg-specific IFNAR deficient (IFNARfl/flxFoxp3YFP-Cre) mice in acute LCMV Armstrong, chronic Clone-13 viral infection, and in tumor models. In both viral infection and tumor models, IFNARfl/flxFoxp3YFP-Cre mice Tregs expressed enhanced Treg associated activation antigens. LCMV-specific CD8+ T cells and tumor infiltrating lymphocytes from IFNARfl/flxFoxp3YFP-Cre mice produced less antiviral and antitumor IFN-γ and TNF-α. In chronic viral model, the numbers of antiviral effector and memory CD8+ T cells were decreased in IFNARfl/flxFoxp3YFP-Cre mice and the effector CD4+ and CD8+ T cells exhibited a phenotype compatible with enhanced exhaustion. IFNARfl/flxFoxp3YFP-Cre mice cleared Armstrong infection normally, but had higher viral titers in sera, kidneys and lungs during chronic infection, and higher tumor burden than the WT controls. The enhanced activated phenotype was evident through transcriptome analysis of IFNARfl/flxFoxp3YFP-Cre mice Tregs during infection demonstrated differential expression of a unique gene signature characterized by elevated levels of genes involved in suppression and decreased levels of genes mediating apoptosis. Thus, IFN signaling in Tregs is beneficial to host resulting in a more effective antiviral response and augmented antitumor immunity.

Publication types

  • Research Support, N.I.H., Intramural

MeSH terms

  • Animals
  • Antiviral Agents / pharmacology
  • Arenaviridae Infections / drug therapy
  • Arenaviridae Infections / immunology*
  • Arenaviridae Infections / metabolism
  • Arenaviridae Infections / virology
  • CD8-Positive T-Lymphocytes / drug effects
  • CD8-Positive T-Lymphocytes / immunology
  • CD8-Positive T-Lymphocytes / metabolism
  • Cells, Cultured
  • Colonic Neoplasms / drug therapy
  • Colonic Neoplasms / immunology*
  • Colonic Neoplasms / metabolism
  • Colonic Neoplasms / virology
  • Immunity, Innate / drug effects
  • Immunity, Innate / immunology
  • Interferon Type I / pharmacology*
  • Interferon-gamma / metabolism
  • Lymphocytic Choriomeningitis / drug therapy
  • Lymphocytic Choriomeningitis / immunology*
  • Lymphocytic Choriomeningitis / metabolism
  • Lymphocytic Choriomeningitis / virology
  • Lymphocytic choriomeningitis virus / drug effects
  • Melanoma, Experimental / drug therapy
  • Melanoma, Experimental / immunology*
  • Melanoma, Experimental / metabolism
  • Melanoma, Experimental / virology
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Receptor, Interferon alpha-beta / physiology
  • Signal Transduction / drug effects
  • T-Lymphocytes, Regulatory / drug effects
  • T-Lymphocytes, Regulatory / immunology*
  • T-Lymphocytes, Regulatory / metabolism
  • T-Lymphocytes, Regulatory / virology
  • Tumor Microenvironment / drug effects
  • Tumor Microenvironment / immunology*

Substances

  • Antiviral Agents
  • Ifnar1 protein, mouse
  • Interferon Type I
  • Receptor, Interferon alpha-beta
  • Interferon-gamma

Grants and funding

This research was supported by the Intramural Research Program of the NIAID, NIH. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.